Use of Bayesian statistics in drug development: Advantages and challenges
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
MAINLY, TWO STATISTICAL METHODOLOGIES ARE APPLICABLE TO THE DESIGN AND ANALYSIS OF CLINICAL TRIALS: frequentist and Bayesian. Most traditional clinical trial designs are based on frequentist statistics. In frequentist statistics prior information is utilized formally only in the design of a clinical trial but not in the analysis of the data. On the other hand, Bayesian statistics provide a formal mathematical method for combining prior information with current information at the design stage, during the conduct of the trial, and at the analysis stage. It is easier to implement adaptive trial designs using Bayesian methods than frequentist methods. The Bayesian approach can also be applied for post-marketing surveillance purposes and in meta-analysis. The basic tenets of good trial design are same for both Bayesian and frequentist trials. It has been recommended that the type of analysis to be used (Bayesian or frequentist) should be chosen beforehand. Switching to an analysis method that produces a more favorable outcome after observing the data is not recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sterne, J. A. C. (2001) · BMJ · doi:10.1136/bmj.322.7280.226 · Cited by 1,466
Adaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482 · cited 3×
“The fl exibility of adaptive design methods, however, may introduce possible operational biases and consequently have an impact on the overall type I error rate.[14] Even though the control of the type I error rate is not a relevant property of a Bayesian design, simulations can be used to design a Bayesian adaptive t…”
Bayesian Computation and Model Selection Without Likelihoods
Leuenberger, C., & Wegmann, D. (2010) · Genetics · doi:10.1534/genetics.109.109058 · Cited by 175
Cited by
Drawbacks of artificial intelligence and their potential solutions in the healthcare sector.
khan, B., Fatima, H., Qureshi, A., Kumar, S., Hanan, A., Hussain, J., & Abdullah, S. (2023) · Biomedical Materials & Devices · doi:10.1007/s44174-023-00063-2 · Cited by 461
“On the other hand, where knowledge is lacking, domain-agnostic generative AI methods are suitable; Bayesian reasoning and deep learning networks are considered well suited combination [51, 52].”
BackgroundHamamoto, R., Suvarna, K., Yamada, M., Kobayashi, K., Shinkai, N., Miyake, M., Takahashi, M., Jinnai, S., Shimoyama, R., Sakai, A., et al. (2020) · Cancers · doi:10.3390/cancers12123532 · Cited by 207
Bartelink, I. H., Jones, E. F., Shahidi‐Latham, S. K., Lee, P. R. E., Zheng, Y., Vicini, P., van ‘t Veer, L., Wolf, D., Iagaru, A., Kroetz, D. L., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1211 · Cited by 96
Metadata
- Authors
- Gupta, S.
- Venue
- International Journal of Applied and Basic Medical Research
- Publisher
- Medknow
- Published
- 2012
- Volume
- 2
- Issue
- 1
- Pages
- 3
- ISSN
- 2229-516X (ISSN-L)
- OpenAlex
- W2168340028
- Cited by
- 60
- References
- 3
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Bayesian statistics in drug development: Advantages and challenges. https://app.cochat.ai/papers/10.4103/2229-516x.96789
- The paper
- Gupta, S. (2012). Use of Bayesian statistics in drug development: Advantages and challenges. International Journal of Applied and Basic Medical Research. https://doi.org/10.4103/2229-516x.96789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.